Wednesday, 18 November 2020 21:36

 

South Africa has recorded 2 888 new coronavirus cases bringing the total number to 757 144.  In a statement, the Department of Health also reported 123 new COVID-19 related deaths.

The cumulative number of tests conducted to date is 5 189 580 with 28 703 new tests conducted since the last report.

A further 123 more COVID-19 related deaths have been reported: Eastern Cape 35, Free State 31, Gauteng 4, Kwa-Zulu Natal 3, Limpopo 7, North West 31 and Western Cape 12,said the department.

This brings the total deaths to 20 556. Of the 123 deaths 17 reportedly occurred in past 24 hours: 4 in Eastern Cape, 2 in Gauteng, 11 in Western Cape.

The recoveries now stand at 701 534 which translates to a recovery rate of 92,6%.

Meanwhile United States pharma giant Pfizer Inc and its German partner BioNTech said on Wednesday that final results from the Phase 3 trial of their COVID-19 vaccine showed it to be 95 percent effective – the highest success rate for any pandemic candidate in late-stage trials so far.

The drug companies will now submit an application with the US Food and Drug Administration for Emergency Use Authorization (EUA) "within days"and to share trial data with other regulatory agencies around the globe, said Pfizer.

"The study results mark an important step in this historic eight-month journey to bring forward a vaccine capable of helping to end this devastating pandemic,"said Pfizer chief Albert Bourla in a statement. "We continue to move at the speed of science to compile all the data collected thus far and share with regulators around the world."

Before the FDA authorises any COVID-19 vaccine for emergency use, officials will review and discuss the trial data in a public meeting likely to take place next month, said Pfizer.

Pfizer and BioNTech expect to produce up to 50 million vaccine doses globally this year and as many as 1.3 billion doses by the end of 2021.

If the FDA grants emergency use, it will still be months before the vaccine is widely available. Governments though are expected to give priority to groups such as front-line healthcare workers and immunocompromised individuals to receive the vaccine this year.

The Pfizer-BioNTech late-stage trial involved nearly 44,000 volunteers, of which 42 percent globally and 30 percent in the US had diverse backgrounds.

The results showed the vaccine to be consistently effective across people of different ages, races and ethnicities. For people above 65, the vaccine was shown to be 94 percent effective, said Pfizer.

Some 170 infections were observed in the study, eight of which were observed in people who received the vaccine rather than a placebo. One of those eight who received the vaccine developed a severe case of COVID-19.

The trial will continue to collect data on efficacy and safety for two more years.

Wednesday’s announcement comes a week after initial results from the trial showed the vaccine was more than 90 percent effective and days after Moderna Inc released promising preliminary trial data for its COVID-19 vaccine that showed it be 94.5 percent effective.

Compiled by Lehlohonolo Lehana.